5.53
0.20 (3.75%)
| Previous Close | 5.33 |
| Open | 5.34 |
| Volume | 6,079,576 |
| Avg. Volume (3M) | 4,041,465 |
| Market Cap | 1,696,760,704 |
| Price / Earnings (TTM) | 50.27 |
| Price / Earnings (Forward) | 34.36 |
| Price / Sales | 5.46 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 10.12% |
| Operating Margin (TTM) | 31.65% |
| Diluted EPS (TTM) | 0.100 |
| Quarterly Revenue Growth (YOY) | 18.20% |
| Quarterly Earnings Growth (YOY) | 23.80% |
| Current Ratio (MRQ) | 2.36 |
| Operating Cash Flow (TTM) | 29.43 M |
| Levered Free Cash Flow (TTM) | 39.45 M |
| Return on Assets (TTM) | 10.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | MannKind Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.86% |
| % Held by Institutions | 58.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nitorum Capital, L.P. | 30 Jun 2025 | 7,011,515 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Oppenheimer, 171.25%) | Buy |
| Median | 10.50 (89.87%) | |
| Low | 8.00 (RBC Capital, 44.67%) | Buy |
| Average | 11.00 (98.92%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 5.06 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Oct 2025 | 11.00 (98.92%) | Buy | 5.10 |
| 18 Sep 2025 | 11.00 (98.92%) | Buy | 5.61 | |
| Oppenheimer | 05 Sep 2025 | 15.00 (171.25%) | Buy | 5.54 |
| Wells Fargo | 03 Sep 2025 | 10.00 (80.83%) | Buy | 5.51 |
| RBC Capital | 26 Aug 2025 | 8.00 (44.67%) | Buy | 4.07 |
| 07 Aug 2025 | 7.00 (26.58%) | Buy | 3.43 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |